Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE

All products: general benefit

Other products in the same Health Canada class (J05AR) — coverage varies; not interchangeable

  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir + lamivudine (Kivexa): general benefit
  • Bictegravir + emtricitabine + tenofovir alafenamide hemifumarate (Biktarvy): general benefit
  • Cabotegravir + rilpivirine (Cabenuva): general benefit
  • Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil (Stribild): general benefit
  • Cobicistat + darunavir (Prezcobix): general benefit

48 more in the class list below

Odefsey · DIN 02461463 · 200mg & 25mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Odefsey · DIN 02461463 Manufacturer: Gilead Sciences Canada, Inc.; listing date 2018-08-30 Health Canada: Marketed since 2017-03-20 · brand ODEFSEY · ATC J05AR19 EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND RILPIVIRINE, J05AR19 EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND RILPIVIRINE · form Tablet · route Oral · ingredients TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) 25 MG, EMTRICITABINE 200 MG, RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE) 25 MG · company Gilead sciences canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Odefsey: Formulary list price $43.3837/unit (unit not stated in source; not the patient's cost)

Ministry pays: $43.3837 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94909 · Verify on the e-Formulary ↗ (DIN 02461463)

Source record
DIN 02461463: Odefsey Raw flags: sec3=Y Item: 081800390; group id 82; item number 0150; lccId None; manufacturer id GIL Source form: Tab; strength: 200mg & 25mg & 25mg Recorded listing: General benefit Source prices (unrounded): $43.3837; ministry $43.3837 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461463 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94909
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461463
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit

COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 150mg & 150mg & 200mg & 300mg · Tab

DARUNAVIR & COBICISTAT

· 1 products · General benefit · strengths: 800mg & 150mg · Tab

DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE

· 1 products · General benefit · strengths: 800mg & 150mg & 200mg & 10mg · Tab

DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE

· 1 products · General benefit · strengths: 50mg & 600mg & 300mg · Tab

DOLUTEGRAVIR & RILPIVIRINE

· 1 products · General benefit · strengths: 50mg & 25mg · Tab

DOLUTEGRAVIR SODIUM/LAMIVUDINE

· 1 products · General benefit · strengths: 50mg & 300mg · Tab

DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 100mg & 300mg & 300mg · Tab

EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE

· 7 products · General benefit · strengths: 600mg/300mg/200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: adults infected with hiv-1 with no known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL · General benefit INDICATIONS AND CLINICAL USE COMPLERA® (emtricitabine [FTC]/rilpivirine [RPV]/tenofovir disoproxil fumarate [TDF]) is indicated for use as a complete regimen for the treatment of adults infected with HIV-1 with no known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or FTC, and with a viral load less than or equal to 100,000 copies/mL. PM: https://pdf.hres.ca/dpd_pm/00053856.PDF; date October 17, 2019; DIN 02374129; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. INDICATIONS ODEFSEY (emtricitabine [FTC]/rilpivirine [RPV]/tenofovir alafenamide [TAF]) is indicated as a complete regimen for the treatment of adults infected with HIV-1 with no known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or FTC, and with a viral load ≤ 100,000 copies/mL. The safety and efficacy of ODEFSEY has not been established in patients with a prior history of virologic failure. The following points should be considered prior to the initiation of therapy in patients with no antiretroviral treatment history:  Regardless of HIV-1 RNA at the start of therapy, more RPV-treated patients with CD4+ cell count less than 200 cells/mm3 at the start of therapy experienced virologic failure compared to patients with CD4+ cell count greater than or equal to 200 cells/mm3.  The observed virologic failure rate in RPV-treated patients conferred a higher rate of overall treatment resistance and cross-resistance to the NNRTI class compared to the control (efavirenz) (see WARNINGS AND PRECAUTIONS, Resistance/Cross- resistance, MICROBIOLOGY, Resistance… https://pdf.hres.ca/dpd_pm/00053935.PDF PM date: November 13, 2019 Source product: ODEFSEY; DIN 02461463; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.